Get started
Author

Hacène Zerazhi

Observed names: H. Zerazhi, Hacene Zerazhi
OpenAlex ID: A5114056842
ASXL1 mutation is associated with poor prognosis and acute transformation in chronic myelomonocytic leukaemia
2010 · Véronique Gelsi‐Boyer, Virginie Trouplin, et al. · British Journal of Haematology · 226
Isatuximab, carfilzomib, lenalidomide, and dexamethasone induction in newly diagnosed myeloma: analysis of the MIDAS trial
2025 · Aurore Perrot, Cyrille Touzeau, et al. · Blood · 42
Long-term outcome of imatinib 400 mg compared to imatinib 600 mg or imatinib 400 mg daily in combination with cytarabine or pegylated interferon alpha 2a for chronic myeloid leukaemia: results from the French SPIRIT phase III randomised trial
2021 · Francois Guilhot, Françoise Rigal-Huguet, et al. · Leukemia · 30
Oxaliplatin before autologous transplantation in combination with high-dose cytarabine and rituximab provides longer disease control than cisplatin or carboplatin in patients with mantle-cell lymphoma: results from the LyMA prospective trial
2021 · Benoit Tessoulin, David Chiron, et al. · Bone Marrow Transplantation · 24
PDF
A randomised phase II study of azacitidine ( AZA ) alone or with Lenalidomide ( LEN ), Valproic acid ( VPA ) or Idarubicin ( IDA ) in higher‐Risk MDS or low blast AML : GFM 's “pick a winner” trial, with the impact of somatic mutations
2022 · Lionel Adès, Nicolas Duployez, et al. · British Journal of Haematology · 23
Myelodysplastic syndromes with single neutropenia or thrombocytopenia are rarely refractory cytopenias with unilineage dysplasia by World Health Organization 2008 criteria and have favourable prognosis
2016 · Emmanuel Gyan, Valérie Andrieu, et al. · British Journal of Haematology · 19
PDF
Daily practice management of myelodysplastic syndromes in France: data from 907 patients in a one-week cross-sectional study by the Groupe Francophone des Myelodysplasies
2009 · C. Kelaidi, A. Stamatoullas, et al. · Haematologica · 19
PDF
Oneversustwo high‐dose cytarabine‐based consolidation before autologous stem cell transplantation for young acute myeloblastic leukaemia patients in first complete remission
2005 · Eric Jourdan, Françoise Rigal‐Huguet, et al. · British Journal of Haematology · 12
Lomustine is beneficial to older AML with ELN2017 adverse risk profile and intermediate karyotype: a FILO study
2020 · Laetitia Largeaud, Pascale Cornillet-Lefebvre, et al. · Leukemia · 11
PDF
Real-world effectiveness of ixazomib combined with lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: the REMIX study
2023 · M. Macro, C. Hulin, et al. · Annals of Hematology · 9
PDF
Molecular classification and prognosis in younger adults with acute myeloid leukemia and intermediate‐risk cytogenetics treated or not by gemtuzumab ozogamycin: Final results of the GOELAMS/FILO acute myeloid leukemia 2006‐intermediate‐risk trial
2021 · Anne Bouvier, Jean‐François Hamel, et al. · European Journal Of Haematology · 9
Development and Validation of the FIP Score for the Screening of FIP1L1::PDGFRA-Associated Hypereosinophilic Syndrome
2025 · Romain Stammler, Alexandre Vallée, et al. · The Journal of Allergy and Clinical Immunology In Practice · 5
Ixazomib, pomalidomide and dexamethasone in relapsed or refractory multiple myeloma characterized with highrisk cytogenetics: the IFM 2014-01 study
2024 · Arthur Bobin, Salomon Manier, et al. · Haematologica · 3
PDF
18-Months Follow-up of the Trial of Imatinib after Ponatinib Induction (TIPI) in the Front-Line Treatment of Chronic Phase (CP) Chronic Myeloid Leukemia (CML) Setting
2024 · Franck E. Nicolini, Aude Charbonnier, et al. · Blood · 3
T rial of Imatinib after Ponatinib Induction (TIPI) in the Front-Line Treatment of Chronic Phase (CP) Chronic Myeloid Leukemia (CML) Setting. Report of the First Therapeutic Sequence
2023 · Franck E. Nicolini, Aude Charbonnier, et al. · Blood · 2
Myelodysplastic Syndrome (MDS) in France: Results of a One-Week Cross-Sectional Survey on Daily Practice Management in 919 Patients by the GFM
2008 · C. Kelaidi, Aspasia Stamatoullas, et al. · Blood · 2
59 Myelodysplastic syndromes with isolated neutropenia or thrombocytopenia: Are they refractory cytopenias with unilineage dysplasia? A GFM registry study
2011 · E. Gyan, V. Andrieu, et al. · Leukemia Research · 1
Ixazomib, Pomalidomide and Dexamethasone (IxPd) in Relapsed or Refractory Multiple Myeloma (RRMM) Characterized with High-Risk Cytogenetics. IFM 2014-01
2023 · Arthur Bobin, Salomon Manier, et al. · Blood
PDF
Pb1755: Clinical Features and Biological Characterization of Adult Patients With Acute Lymphoblastic Leukemia Treated in a Regional Hospital in France
2023 · Pilar Dutari, Tantrantan Leonce Adjoumani, et al. · HemaSphere
A Second Course of High-Dose Cytarabine before Autologous Stem Cell Transplantation Does Not Improve Outcome of Young Acute Myeloid Leukemia Patients in First Complete Remission: Results of the BGMT 95 Study.
2004 · Eric Jourdan, Françoise Rigal-Huguet, et al. · Blood
Works count: 21
Citation count: 448
H-index: 10
I10-index: 10
Year
Topic
Type